Campus Review Vol 29. Issue 9 september 2019 | Page 7

news campusreview.com.au Tough as old boots Aussie men live longest, research reveals. I f you’re an Australian man, you’re better placed than any other male group in the world to reach a ripe old age. This is according to new research by ANU. Pulling data from 15 countries with high life expectancies across Europe, North America and Asia, the study authors found that Aussie men live to an average of 74.1 years. The four runner-up groups were men in Nordic and European countries, with Sweden a close second (74.0) followed by Switzerland (73.7). Brain in a dish How new technology might help children with dementia. C hildhood dementia might sound like a misnomer to some, but five Australians every year are born with an untreatable form of the disease. Now, South Australian researchers will use ‘brain in a dish’ technology to improve the lives of those diagnosed with Sanfilippo syndrome, and possibly others living with more common neurological diseases. The study also found that Australian women have the second- highest life expectancy in the world (78.8 years); Swiss women live an average 0.2 years longer. "Popular belief has it that Japan and the Nordic countries are doing really well in terms of health, wellbeing and longevity. But Australia is right there," said the study’s lead researcher Dr Colin Payne. "The results have a lot to do with long term stability and the fact Australia's had a high standard of living for a really, really long time. Simple things like having enough to eat and not seeing a lot of major conflict play a part." The study introduced a new way of measuring life expectancy, grouping individuals who were born in the same year into cohorts, rather than assessing mortality rates of the population en masse. In doing so, the researchers brought historical nuance and situational factors to bear on the data, so that they could compare groups who have “experienced similar conditions throughout their life”. These conditions could be war, disease or any other kind of socio-historical circumstance that has a non-negligible impact on mortality. "For example, any Australian man who's above age 74 we know with 100 per cent certainty has outlived half of his cohort – he's an above average survivor compared to his peers born in the same year," Payne said. "And those figures are higher here than anywhere else that we've measured life expectancy. "On the other hand, any man who's died before age 74 is not living up to their cohort's life expectancy." The research was published in the journal Population Studies. ■ Associate Professor Kim Hemsley and Dr Nicholas Smith. Photo: Tom Huntley/News Corp Australia The degenerative condition presents in early childhood following an initial period of normal development. Over time, those living with the disease experience declining brain function with hyperactive behaviour, sleep disorder, seizures and loss of mobility. Life expectancy for children with Sanfilippo is between 12 and 20 years. The new research will explore whether existing drugs can be rapidly repurposed to help those living with the genetic condition. To do so, the team will take skin cells from patients, reverse engineer them into stem cells and then develop them into neural cells to create a representation of the person’s brain. Associate Professor Kim Hemsley from SAHMRI’s Lifelong Health Theme said by using a patient’s own cells, the researchers can create a targeted, personalised treatment plan. “The other benefit is we can grow a significant number of these ‘brains in dishes’, meaning we can fast-track the testing of a range of drugs that have already been given safety approval for human use,” Hemsley said. Dr Nicholas Smith, from the University of Adelaide and the Women’s and Children’s Hospital, said those living with rare diseases are historically underserved from a research perspective, particularly in paediatrics. SAHMRI, the Women’s and Children’s Hospital and the University of Adelaide partnered with the Sanfilippo Children’s Foundation to secure $2.5 million for the project. The team secured $2 million from the federal government’s Medical Research Future Fund (MRFF), and the foundation will front a further $500,000 of its own funds. ■ 5